A B S T R A C T Cryoglobulins were examined in a standardized manner in an unselected group of 35 patients with rheumatoid arthritis (RA) and 8 patients with RA complicated by cutaneous vasculitis and neuropathy. Optimum conditions for detection and characterization of cryoglobulins were established; the proportion of resolubilized to total precipitable protein remained constant in an individual patient under these conditions. All 8 vasculitis patients and 9 of 35 other patients with RA exhibited cryoglobulins; total protein and immunoglobulin content were significantly higher in the cryoglobulins of patients with vasculitis. Immunoglobulins G and M constituted two-thirds and three-quarters of the total protein in the cryoglobulins from uncomplicated rheumatoid and vasculitis patients, respectively. Serum antiglobulin titers were higher, and serum C3 levels were lower, in vasculitis patients compared to rheumatoid patients without vasculitis.
INTRODUCTION
Cryoglobulins, or cold-precipitable immune globulins, were first observed in the setting of reticuloendothelial malignancy (1) . Subsequent studies of these proteins have focused largely on the physicochemical nature of cryoprecipitation and the immunochemical properties that determine their unique solubility characteristics (2) . Fourteen years after the original observation a patient was described who exhibited a similar phenomenon in the absence of malignancy and whose clinical features suggested an immunologically mediated disease (3) . In recent years the emphasis of investigations concerning these proteins has changed. Now they are being viewed as circulating immune complexes because of the demonstration that they contain appropriate antigens, antibodies, or other immunoreactants that may relate to the pathogenesis of the disease they accompany (4) . For example, cryoglobulins occur regularly in the sera of patients with diseases of known infectious etiology associated with "autoimmune" features, such as infectious mononucleosis (5, 6) , leprosy (7), poststreptococcal glomerulonephritis (8), cytomegalovirus syndromes (6, 9) , subacute bacterial endocarditis (10, 11) , and tropical splenomegaly syndrome, resulting from chronic malarial exposure (12) . Cryoglobulins have, in addition, been described in rheumatic disorders of unknown etiology such as systemic lupus erythematosus (13) , the "purpura-wi-t\etkiness-artlhr-algia" syndrome (14) , immunologic syndromes involving the kidney (15) and in New Zealand Black mice (16) , and in a primary or "essential" form (17) .
In rheumatoid arthritis (RA),' cryoglobulins (18, 19) and immune complexes (20) are found in synovial fluid and these are thought to play a role in the pathogenesis of the articular inflammation that occurs in that disease (21) . In the sera of such patients, however, immune complexes are only occasionally demonstrated (22) , and spontaneous precipitates are infrequently recognized in refrigerated rheumatoid sera (23, 24) . When large numbers of patients with systemic "autoiimmune' diseases are screened for cryoglobulins, some patients with RA are noted (25, 26) .
In order to determine the true incidence and the biologic significance of cryoglobulins in RA, a systematic analysis has been carried out. The data presented demonstrate that cryoglobulins are regularly detected in rheumatoid sera when a standardized methodology is used. The amount of cryoprecipitable protein is smaller than that usually found in other cryoglobulinemic syndromes. Rheumatoid cryoglobulins contain immunoglobulins and complement components. They have specific antibody activity, primarily anti-gamma globulin. RA patients with the largest amounts of cryoglobulins in their circulation also had systemic (i.e., vascular) complications of RA. Long-term serial studies of vasculitis patients treated with the immunosuppressive agent cyclophosphamide disclosed an association between the presence of cold-precipitable IgG-anti-gamma globulin complexes and the systemic vascular features of RA. The nature of this association is discussed.
METHODS
Patients. Samples were obtained from 38 patients with RA, who were encountered in follow-up visits to a rheumatology clinic or hospitalized for either orthopedic or medical complications of their disease. They were chosen at random over a 6-mo period (January-June 1972). Patients with rheumatoid vasculitis were chosen consecutively as they were identified over a 12-mo period (January-December 1972). Patients with RA were representative of a total population of clinic-based rheumatoids; patients with vasculitis were either discovered in our clinic based population (W. H.), referred to our rheumatology division for evaluation of vasculitis (J. S., D. A., M. H., and L. T.), or hospitalized at the Veterans Administration Hospital for vasculitis (D. M., J. S., and R. M.). All patients (including those with vasculitis) met the American Rheumatism Association criteria for definite or classical RA (27) .
Collection of sera and quantitation of the cryoglobulins.
All samples were handled in identical fashion. Blood was drawn into sterile glass tubes (Vacutainer, Becton-Dickinson & Co., Rutherford, N. J.) and allowed to clot at 370C
'Abbreviations used in this paper: BDB, bis-diazotized benzidine; RA, rheumatoid arthritis.
in a water bath. Serum was obtained after centrifugation at 1,500 g for 10 min at room temperature. 5 ml of serum was kept at 4VC for 72 h. After centrifugation at 1,500 g for 10 min at 4°C the supernate was decanted and saved. The precipitate formed was washed three times with an excess of cold normal saline (0.15 M). Solubilization of the precipitate took place in two steps: first in 0.5 ml of twice normal saline (0.3 M) with incubation for 1 h at 37°C, then 0.5 ml of distilled water was added followed( by iMcubationi for another hour at 37°C. The final 1-ml solution in normal saline (0.15 M) was centrifuged at room temperature; any insoluble material was discarded. The specimens were kept at room temperature throughout the series of experiments.
In studies examining alternative methods for solubilizing the cryoprecipitates 15 ml of fresh rheumatoid serum was divided into three equal parts. The procedure was the same as that described above up to the final wash in cold normal saline. At that point the packed cryoglobulins were solubilized with either 1.0 ml of 1 N NaOH or 1.0 ml of 0.06 M glycine HCl (pH 3.2) or the regular two-step procedure of 0.5 ml of 0.3 M NaCl followed by 0.5 ml of water. In another series of experiments cryoprecipitates solubilized by the routine method were compared to those solubilized in 1.0 ml of 0.06 M glycine HCl (pH 3.2) at 37'C for 1 h, followed by neutralization with the addition of a few drops of 1.0 N NaOH. The neutralized, solubilized cryoprecipitate was then dialyzed overnight at room temperature against a large volume of normal saline.
Characterization of the cryoglobulins. The total protein was measured by the Lowry method using an IgG standard of known protein content (28) . The concentrations of specific immunoglobulins were determined by radial immunodiffusion in gel employing commercial monospecific antibodies for IgA and IgM (Hyland Div., Travenol Laboratories, Inc., Los Angeles). The lower limit of detection of IgM was 0.04 mg/ml and IgA was 0.02 mg/ml. IgG concentrations were measured in a similar manner with a rabbit anti-human IgG antibody, which, at a concentration of 2%o (0.2 ml antisera to 9.8 ml 1%o agarose in 0.06 M (30) . Serum (lilutions were in normal saline.
Cryoglobulins were diluted in normal saline containing 1.0 Cryoimmunoglobulinemia in Rheumatoid Arthritis 727 mg/ml of bovine serum albumin. Cold-reactive antiglobulins were determined after overnight incubation at 4VC. Precipitin reactions were performed in 1% agar with the test material in a central well surrounded by wells containing heataggregated (630C for 20 min) human IgG in concentrations ranging from 1.0 to 0.125 mg/ml. The plates were maintained at room temperature and read at 24 to 48 h. The immunoglobulin class of the anti-gamma globulin factors was determined by absorption to insolubilized human IgG (Cohn fraction II). Insoluble IgG was prepared by cross linking with bis-diazotized benzidine (BDB) by the method of Ishizaka, Ishizaka, Salmon, and Fudenberg (31) . Serum samples of 1.0 ml at a 1: 2 dilution or undiluted cryoprecipitates in a volume of 1.6 ml were incubated with 10 mg of BDB-aggregated IgG for 1 h at 370C and then 2 h at 4VC. Aggregates were packed by centrifugation at 500 rpm for 20 min at 40 C and the supernates decanted. The packed aggregates were resuspended in borate-buffered normal saline (pH 8.0) and incubated for 1 h at 370C. After incubation the mixture was centrifuged, the wash discarded, and the bound protein was eluted by incubation for 1 h at 37°C with 0.5 ml of a 0.1 M acetate buffer (pH 4.2). The precipitate was repacked by centrifugation and the supernate containing the eluted immunoglobulin was carefully removed with a Pasteur pipette. The eluates were neutralized immediately with 0.1 M NaOH and analyzed for immunoglobulin content and anti-gamma globulin activity.
Reduction and alkylation of serum and cryoprecipitates with 0.1 M 2-mercaptoethanol and 0.02 M iodoacetamide was accomplished as described (32 The relationship between total amount of cryoprecipitable protein and the amount resolubilized for consecutive samples in three patients. and were often more difficult to plays the relationship between cryoprecipitate and the amount solubilize. Fig. 1 disthe total amount of resolubilized for consecutive samples, followed over time in three patients. Percentage Fig. 2 compares the serum titers of antinuclear and anti-gamma globulin antibodies of patients with cryoglobulins to those who did not have cryoprecipitates. Rheumatoid sera that formed cryoglobulins had significantly higher titers of rheumatoid factors (P = 0.01) but not antinuclear antibodies (P = 0.10).
The relationship between the antibody constituents of the cryoglobulin and the corresponding serum level of the same antibody was analyzed. Cryoglobulins containing antinuclear antibodies (three) were more likely to come from sera containing high titers of antinuclear factors. The small number precludes meaningful statistical analysis. This association was not true for antigamma globulin factors. The rheumatoid factor titers of the cryoglobulins were independent of the serum titers (P = 0.50 by linear regression analysis). In addi- (Table III) .
All patients had dermal vasculitis with skin infarction. Three had frank digital gangrene. Rheumatoid nodules were palpated in six patients.
Immunologic features. Rheumatoid factor was present in significantly higher titers in the serum of patients with vasculitis than in those without vasculitis (P <0.001) (Fig. 4) . Although there appears to be a trend, there was no significant statistical difference (P = 0.06) between the rheumatoid factor titers of vasculitis patients and the nine rheumatoids with cryoglobulins without vasculitis. Antinuclear factor was detected in a few members of each group, but the titer elevations were not different. Serum C3 levels (Fig. 5) were not significantly lower in patients with vasculitis (mean, 129 mg/100 ml) when compared to rheumatoids with cryoglobulins but without vasculitis (mean, 148 mg/100 ml), but the mean C3 concentration of the vasculitis patients was significantly lower than the mean of 154 mg/100 ml for the entire group of 35 patients with RA without vasculitis (P = < 0.01).
Comparison of RA cryoglobulins and RA vasculitis cryoglobulins. As noted above, rheumatoid patients were said to have cryoglobulins if the protein concentration of the cryoglobulin is equal to or greater than 0.15 mg/ml. By this definition, all of the eight vasculitis patients exhibited cryoglobulins; they will be compared to the nine cryoglobulins from rheumatoids without vasculitis.
Composition. The total protein of the vasculitis cryoglobulins ranged from 0.15 to 0.66 mg/ml with a mean of 0.37 mg/ml ( Fig. 6 and Table IV ). This was significantly higher than found in the cryoglobulins from rheumatoid patients without vasculitis (P= 0.01). All eight vasculitis cryoglobulins contained measurable amounts of IgG and IgM, accounting for more than 75% of the total protein. The mean IgG and IgM concentrations were 0.14 and 0.15 mg/ml both of which were significantly higher than found in the rheumatoid cryoglobulins (P = 0.01 for IgG, P = 0.03 for IgM). There was no difference between the two groups of patients in the frequency of antinuclear factors or complement components (Clq or C3) detected in their cryoglobulins.
Anti-gamma globulin activity. All eight vasculitis cryoglobulins contained anti-gamma globulin activity (Table IV) A number of experiments were done to de munoglobulin class of the anti-IgG antibodi cryoglobulins were examined for anti-gami activity by the bentonite flocculation test beft treatment with 2-mercaptoethanol. All act serum was removed by the treatment. Init peared that the cryoprecipitates were resist captoethanol, with at most a one or two tu' in titer. Subsequently, it was found that re lowed by alkylation eliminated the rheumatoid factor activity, suggesting that recombination occurred in the absence of the alkylating agent (iodoacetamide). This was further supported by the observation that the antigamma globulin activity was destroyed by reduction alone if the cryoglobulin (0.1 ml) was added to normal human serum (0.4 ml) before reduction.
Sucrose density gradients were run in acid buffers to prevent reassociation of the cryoprecipitates in the cold. In more than a dozen studies, with but one exception, the anti-gamma globulin activity was cyclophosphamide at 100-150 mg/day. The course of one of them (M. H.) is shown in Fig. 7 . In this patient the cryoglobulin disappeared from her serum by the 8th wk of therapy and never returned during the 4-mo observation period. The other patient (not shown) had a small cryoglobulin initially (0.15 mg/ ml), which disappeared within 1 wk of therapy and did not return during 1 yr observation. M. H.'s serum rheumatoid factor activity diminished and was no longer detectable at 10 wk. In the other patient, it was significantly reduced (from 1: 2,560 to 1: 80) at 12 wk. Neither patient exhibited new signs of vasculitis once treatment had begun. R. M. (Fig. 8) was treated with two intravenous doses of cyclophosphamide (480 mg each), but concomitant infection prevented the use of oral maintenance therapy. The amount of cryoglobulins diminished only slightly, and the serum rheumatoid factor fell two tube dilutions. However, the anti-gamma globulin activity of the cryoglobulin declined to zero and was only detected once after the 11th wk after intravenous therapy. IgM could not be measured in the cryoglobulin after the 15th wk. Evidence of further vasculitis was not observed during the 24 wk of follow-up.
A fourth patient (D. A.) was treated with oral cyclophosphamide, 150 mg/day. Her serum rheumatoid factor remained unchanged during the 8-mo observation period, but the cryoglobulin disappeared. The clinical signs of vasculitis regressed.
An additional patient (J. S.) received two intravenous doses of cyclophosphamide (500 mg) each. Oral therapy was attempted, but could not be continued because of gastrointestinal and bladder toxicity. Throughout the 19 wk of observation, his cryoglobulins tended to increase in amount and the rheumatoid factor activity of the cryoglobulin and the accompanying serum was unchanged. New dermal vasculitic lesions appeared during the first 8-10 wk of his hospital course.
Finally, one patient (L. T.) was followed who did not receive any cyclophosphamide (Fig. 9) . During the 22 wk of observation the cryoglobulin content of her serum did not change appreciably and the rheumatoid factor activity of her cryoglobulin and serum remained constant. She did not exhibit any additional signs of vasculitis despite the persistence of these abnormalities. (36) . There is often no fixed relationship between the starting volume of sera and the final volume of resuspended protein (34) . Alternatively, the final cryoglobulin protein concentration may be adjusted to a standard amount that is suitable for immunochemical studies but makes comparisons of samples from individual patients difficult (6, 35, 37) . Finally, it is often not stated (12, 34, 35) if the cryoglobulin concentration (expressed in milligrams per milliliter) refers to the final volume in which the protein is resuspended or to the volume of starting material.
It has recently been suggested (2) We selected the 0.15-mg/ml protein concentration to designate patients as having cryoglobulins. The reason for this decision was that in the cryoprecipitates with lesser protein concentrations, the immunoglobulins G and M, when detected, made up less than one-third of the total protein. Therefore all vasculitis patients, onethird of rheumatoids without vasculitis, and none of the controls are designated as having cryoglobulins, or "cryoimmunoglobulins." In normal subjects cryoglobulins are either absent (8, 10, 26, 35) or present in limited quantities (5, 12, 34) (47) ; (e) depression of serum complement activity, as well as decreased concentration of several components (C4, C2) are correlated with clinical signs of vasculitis (45, 48, 49) , as is hypercatabolism of C3 (50) .
Peripheral neuropathy in RA correlates with other organ involvement (39, 51) . Histologic gammiiiia globulin followed by elution with acid and estiination of the eluate by radial immunodiffusion using specific anti-immunoglobulins (59) . The method is sufficiently sensitive to detect antibodies to IgG in normal serum. When two isolated cryoglobulins were analyzed in this manner (Table VI) , IgG was identified in the eluates despite the very low concentration of this immunoglobulin in the starting material. One cannot exclude the possibility that a limited number of sites on the immunoabsorbent nonspecifically bind a small amount of IgG. This would explain the similar concentrations of IgG in the various eluates, despite very great differences between the test serum and cryoglobulins. But, Heimer and Abruzzo have shown in a similar system that the protein concentration of the eluted IgG is directly proportional to its anti-IgG activity, whether it comes from normal or rheumatoid serum (60) . Thus, there is conflicting evidence about the antibody nature of the IgG in the cryoprecipitates.
These discrepancies can most likely be ascribed to differences in the sensitivities of the various techniques we used to search for IgG antiglobulins. The simplest explanation is that IgG rheumatoid factor is a minor constituent of the cryoglobulins, probably constituting less than 20% of the IgG in the precipitates. It is important to point out, however, that less than one-third of the total cryoprecipitable protein is extracted by the method we have employed (Fig. 1) . Perhaps the most avid antigen-antibody complexes are not resolubilized and hence not detected. Alternatively, a family of antiIgG complexes may exist in the circulation, but a decreased cold solubility of IgM rheumatoid factor favors its disproportionate representation in the cryoglobulins. In either instance, the cryoglobulins we measure could serve as faithful indicators of the potential for vasculitis while the actual phlogogenic complexes escape recognition.
The natural history of vascular complications of RA is quite variable. This makes evaluation of any form of treatment difficult (40) . However, it has been shown that the presence of extra-articular disease in RA increases mortality twofold (61) , and the presence of mononeuritis multiplex involving three or four extremities is associated with a greater than 40% mortality from vasculitis (62) . Because of these considerations, intravenous cyclophosphamide was given to all five patients with three-or four-extremity mononeuritis multiplex, and oral therapy with the same drug was employed in one patient with two-extremity involvement. 
